The inhibitors target the ATP binding site of the FGFR2 kinase domain and inhibit cell proliferation, which suggests that FGFR2 inhibitors might be effective for cancer with not only FGFR2 fusion but also active abnormalities [7,8]. Here, FGFR2 is linked to cancer.